Showing stories 1 - 10 of about 90
GlaxoSmithKline plc (ADR) (GSK), Sanofi SA (ADR) (SNY), Theravance Inc ...
Starting in reverse, Elan Corporation, plc (ADR) (NYSE:ELN) surprised investors on Monday by coming out of the bleachers and entering into a $1 billion royalty deal with Theravance Inc (NASDAQ:THRX). If you recall, Theravance Inc (NASDAQ:THRX) and ...
Amarin Corporation plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX ...
Theravance Inc. (NASDAQ:THRX) a biopharmaceutical company that engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous ...
NASDAQ Decliners Watch List: Amarin Corporation Plc (NASDAQ:AMRN ...
Wilmington, DE -- (SBWIRE) -- 05/20/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Amarin Corporation plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX), and Dendreon Corp. (NASDAQ:DNDN).
Related articles »
Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc ...
CEO of Theravance Inc. ( THRX ) Rick E. Winningham sold 255,532 shares on 04/30/2013 at an average price of $33.64. Theravance Inc. was incorporated in Delaware in November 1996 under the name Advanced Medicine Inc, and began operations in ...
THERAVANCE INC : BREO(TM) ELLIPTA(TM) gains US approval for the ...
Glaxo, Theravance Lung Disease Drug Gains FDA Approval iStockAnalyst (press release)
Related articles »
LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ...
Glaxo, Theravance Win Approval for Lung Disease Treatment
BloombergGlaxo, Theravance Lung Disease Drug Gains FDA Approval iStockAnalyst (press release)
Related articles »
Theravance Inc. (THRX) Has Spiked To A New High On Plans To Split Company
Theravance Reports First Quarter 2013 Financial Results Marketwire (press release)
Related articles »
(RTTNews.com) - Theravance Inc. ( THRX ) reported a first quarter loss of $0.39 per share after the bell Thursday, compared to the loss of $0.93 in the previous year.
THERAVANCE INC : Theravance Announces Plan to Separate Late-Stage ...
4-traders (press release)Theravance Reports First Quarter 2013 Financial Results Marketwire (press release)
Related articles »
Theravance Inc. (NASDAQ:THRX), Gilead Sciences Inc. (NASDAQ:GILD), and ...
Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical company that discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia is currently up (+2.94%) on 10,887,989 ...
Related articles »
NASDAQ MOST ADVANCED STOCKS: MediciNova, Inc., Canadian Solar Inc ...
Huntington Beach, CA -- (SBWIRE) -- 05/13/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ...
Traders Alert: Theravance Inc (NASDAQ:THRX), Canadian Solar Inc.(NASDAQ ...
Elan enters $1B royalty deal with Theravance Wall Street Journal
Related articles »
Theravance Inc (NASDAQ:THRX) shares increased 10.62% to $38.72. Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) on May 13 announced that they have entered into a royalty participation agreement wherein Elan will purchase ...
Elan to Pay $1 Billion for Stake in Theravance's Royalties (4)
BusinessweekElan enters $1B royalty deal with Theravance Wall Street Journal
Related articles »
Gainers Recap: JA Solar Holdings Co, Theravance Inc, Avalon Rare Metals ...
Theravance Inc. (NASDAQ:THRX) increased 11.59% and closed at $34.94. Elan Corp. facing a takeover offer by Royalty Pharma, agreed to pay $1 billion for a share of the royalties on new drugs that Theravance Inc. will receive from GlaxoSmithKline Plc.
Related articles »